MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.xops.2025.100940

Медицинская библиотека · Ophthalmology science · 2025

One-Year Myopia Control Efficacy of a New Defocus Spectacle Lens: A Randomized Clinical Trial.

Han Xiaotong, Zhang Yurui, Jin Ling, Wang Decai, He Mingguang, Zeng Yangfa

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: To evaluate the efficacy and safety of the new defocus spectacle lens in preventing myopia progression compared with the conventional single-vision spectacle lens (SVL).

DESIGN

A randomized, open-label, controlled clinical trial.

SUBJECTS: Children aged 6 to 14 years with a cycloplegic spherical equivalent refraction (SER) of -1.00 to -3.50 diopters (D) in both eyes were enrolled.

METHODS

Eligible participants were randomly assigned in a 1:1 ratio to receive either the novel defocus spectacle lens (MYOGEN) or the SVL. Data from the right eyes at the 12-month follow-up were used for the current analysis.

MAIN OUTCOME MEASURES: The primary outcome was the 1-year change in SER from baseline to 12 months. Secondary outcomes included changes in axial length (AL), choroidal thickness, subjective visual quality scores, and daily spectacle wear time. Axial length was designated as the main secondary outcome due to its close relationship with myopia progression.

RESULTS

A total of 85 patients were assigned to the MYOGEN group and 89 to the SVL group, with mean (standard deviation) ages of 10.44 (0.92) years and 10.61 (0.73) years, respectively. After 1 year, myopia progression and axial elongation were all significantly less in the MYOGEN group than in the SVL group (SER change: -0.80 ± 0.44 D and -1.06 ± 0.51 D, respectively; AL change: 0.25 ± 0.15 mm and 0.37 ± 0.18 mm, respectively; all P < 0.001). Among patients with good compliance (≥8 hours/day and ≥5 days/week), the treatment effect was even more pronounced for SER (adjusted difference: 0.40 D [95% confidence interval [CI], 0.25 to 0.56]) and AL (adjusted difference: -0.15 mm [95% CI, -0.21 to -0.10]). No significant between-group differences were observed in compliance with spectacle wear and subjective visual quality.

CONCLUSIONS

Compared with the SVL, MYOGEN was shown to reduce myopia progression and axial elongation over the 1-year follow-up period.

FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Для цитирования: Han Xiaotong, Zhang Yurui, Jin Ling, Wang Decai, He Mingguang, Zeng Yangfa. One-Year Myopia Control Efficacy of a New Defocus Spectacle Lens: A Randomized Clinical Trial.. Ophthalmology science. 2025. DOI: 10.1016/j.xops.2025.100940.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.